mylan
FDA Approves Fulphila, First Biosimilar to Neulasta
Mylan's Fulphila is the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile ...
JUNE 4, 2018
FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers
Ogivri is the first biosimilar approved in the United States for the treatment of breast cancer or stomach ...
DECEMBER 1, 2017
Mylan Will Pay $465 Million For Medicare/Medicaid EpiPen Rebates
CMS says that Mylan had repeatedly misclassified EpiPen as a generic drug, rather than a branded drug, for purposes ...
OCTOBER 11, 2016
Load more